Literature DB >> 8856706

An I2 imidazoline ligand, RS 45041, potentiates hyperalgesia in acute arthritis.

A K Houghton1, K N Westlund.   

Abstract

Descending inhibition is increased after the induction of inflammation of the knee. The present study investigated whether this effect is mediated through alpha 2-adrenoceptors and/or I2 imidazoline receptors in the rat. An alpha 2-adrenoceptor antagonist, RX 821002, a selective I2 imidazoline ligand, RS 45041, and idazoxan, which has affinity for both these receptor types, were administered. After the induction of acute arthritis by intra-articular injection of kaolin and carrageenan, the agents binding to I2 imidazoline receptors further reduced the paw withdrawal latency to radiant heat beyond that induced by acute arthritis, i.e. these drugs were pronociceptive, potentiating hyperalgesia. These results suggest that I2 imidazoline receptors have an important role to play in modulation of hyperalgesia during acute inflammation. Development of I2 imidazoline drugs may prove useful in the treatment of hyperalgesia.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8856706     DOI: 10.1097/00001756-199606170-00011

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  3 in total

Review 1.  Neuroanatomy of the pain system and of the pathways that modulate pain.

Authors:  W D Willis; K N Westlund
Journal:  J Clin Neurophysiol       Date:  1997-01       Impact factor: 2.177

2.  Activation of I(2)-imidazoline receptors enhances supraspinal morphine analgesia in mice: a model to detect agonist and antagonist activities at these receptors.

Authors:  P Sánchez-Blázquez; M A Boronat; G Olmos; J A García-Sevilla; J Garzón
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

3.  Antihyperalgesic effects of imidazoline I(2) receptor ligands in rat models of inflammatory and neuropathic pain.

Authors:  Jun-Xu Li; David A Thorn; Yanyan Qiu; Bi-Wen Peng; Yanan Zhang
Journal:  Br J Pharmacol       Date:  2014-03       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.